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ABSTRACT 
Apoptosis is a driving force of diabetic end organ damage, including diabetic nephropathy. 
However, the mechanisms that modulate diabetes-induced cell death are not fully understood. Heat-shock 
protein 27 (HSP27/HSPB1) is a cell stress protein that regulates apoptosis in extrarenal cells and is 
expressed by podocytes exposed to toxins causing nephrotic syndrome. We investigated the regulation of  
HSPB1 expression and its function in podocytes exposed to factors contributing to diabetic nephropathy, 
such as high glucose and angiotensin II. HSPB1 expression was assessed in renal biopsies from patients 
with diabetic nephropathy, minimal change disease or focal segmental glomerulosclerosis, in a rat model 
of diabetes induced by streptozotocin and in angiotensin II-infused rats. The regulation of HSPB1 was 
studied in cultured human podocytes and the function of HSPB1 expressed in response to 
pathophysiologically relevant stimuli was explored by short interfering RNA (siRNA) knock-down. 
Total kidney HSPB1 mRNA and protein expression was increased in rats with streptozotocin-
induced diabetes and in rats infused with angiotensin II. Upregulation of HSPB1 protein was confirmed in 
isolated diabetic glomeruli. Immunohistochemistry showed increased glomerular expression of HSPB1 in 
both models and localized glomerular HSPB1 to podocytes. HSPB1 protein was increased in glomerular 
podocytes from patients with diabetic nephropathy or focal segmental glomerulosclerosis. 
In cultured human podocytes HSPB1 mRNA and protein expression was upregulated by high 
glucose concentrations and angiotensin II. High glucose, but not angiotensin II, promoted podocyte 
apoptosis. HSPB1 siRNA targeting increased apoptosis in a high-glucose milieu and sensitized to 
angiotensin II or TGFβ1-induced apoptosis by promoting caspase activation.  
In conclusion, both high glucose and angiotensin II contribute to HSPB1 upregulation. HSPB1 
upregulation allows podocytes to better withstand an adverse high-glucose or angiotensin II-rich 
environment, such as can be found in diabetic nephropathy. 
 
Abbreviations 
Ang: Angiotensin  
DAPI: 4',6-Diamidino-2-phenylindole dihydrochloride 
DN: Diabetic nephropathy  
DNA: Deoxyribonucleic acid 
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ECL: Enhanced chemiluminescence 
FSGS: Focal Segmental Glomerulosclerosis 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
HSPs: Heat shock proteins  
ITS: Insulin, transferrin, selenite 
MAPK: Mitogen-Activated Protein Kinase 
MCD: Minimal change disease 
PCR: Polymerase chain reaction 
RAS: Renin angiotensin system  
RNA: Ribonucleic acid 
siRNA: Small interfering RNA 
STZ: Streptozotocin 
SV40: Simian virus 40 
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INTRODUCTION 
Diabetic nephropathy (DN) is the most frequent cause of end-stage renal disease. The diabetic milieu 
induces apoptosis in various end-organ systems and contributes to the gradual loss of renal function and 
mass in DN (1-3). Studies in humans and DN animal models reveal podocyte injury, detachment, 
apoptosis, and loss (4-8). Although some stimuli induce necrosis of podocytes in culture (9), there is more 
in vivo evidence for a role of apoptosis in podocyte loss in DN (10-12). More specifically, podocyte 
apoptosis coincided with the onset of albuminuria and preceded podocytopenia in different mouse models 
of diabetes (13). Podocyte apoptosis has also been documented early in the course of kidney disease in 
patients with type 2 diabetes (14). The molecular pathways contributing to podocyte injury in DN include, 
but are not limited to, high glucose and activation of the local renin angiotensin system (RAS) (15). 
Angiotensin (Ang) II is one of the major effector molecules of the RAS and is the main target of 
established therapy for clinical DN (15). Intraglomerular Ang II levels are increased in DN (16), 
podocytes express Ang II receptors (17) and local glomerular RAS directly promotes filtration barrier 
injury (15). Ang II promoted apoptosis of cultured rat and mouse podocytes (18-20). However, Ang II-
induced apoptosis in human podocytes is not well characterized. 
Cells respond to environmental stressors by rapidly synthesizing protective proteins such as heat 
shock proteins (HSPs) (21;22). HSPs are ubiquitous, highly evolutionary conserved intracellular proteins 
categorized according to their molecular weight (23;24). HSPs have chaperone-like activity and protect 
proteins from damage induced by environmental factors, such as free radicals, heat, ischemia and toxins, 
allowing denatured proteins to adopt their native configuration. HSPB1 is a member of the small HSP 
family of proteins with a molecular weight of approximately 27 kDa (25). HSPB1 controls a wide range 
of biological activities, including actin stabilization and protection from stress and apoptosis (25-30). 
HSPB1 may be of particular interest in podocyte injury since its expression is induced by the podocyte 
toxin puromycin aminonucleoside (PAN) (31). Protective cellular responses in podocytes are poorly 
understood. HSPB1 regulates actin microfilament dynamics in podocyte foot processes (31). In addition, 
enhanced podocyte HSPB1 expression/phosphorylation has been reported in experimental nephrotic 
syndrome induced by the podocyte toxin PAN (31) suggesting a role for HSPB1 in the 
pathophysiological changes of the podocyte cytoskeleton during the development of proteinuria. 
However, there is an incomplete understanding of the relationship between podocyte HSPB1 and 
stressors relevant to DN, such as high glucose and angiotensin II. 
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The present study was designed to assess podocyte HSPB1 expression in vivo during kidney 
injury induced by diabetes or following Ang II infusion and the role of HSPB1 on apoptosis in cultured 
human podocytes exposed to either high glucose or Ang II. Our results indicate that HSPB1 upregulation 
is a compensatory protective mechanism that prevents podocyte apoptosis in the presence of Ang II or a 
high glucose milieu. 
 
MATERIAL AND METHODS 
Cell culture and reagents 
Human podocytes are a previously described cell line (32) transfected with a temperature-
sensitive SV40 gene construct and a gene encoding the catalytic domain of human telomerase. At a 
permissive temperature of 33ºC, the cells remain in an undifferentiated proliferative state, whereas raising 
the temperature to 37ºC results in growth arrest and differentiation to the parental podocyte phenotype. 
Undifferentiated podocyte cultures were maintained at 33ºC in RPMI 1640 medium with penicillin, 
streptomycin, ITS (Insulin, transferrin, selenite), and 10% FCS. Once cells had reached 70 to 80% 
confluence, they were cultured at 37ºC for at least 14 days before use, when full differentiation and 
nephron expression had taken place (5). Experiments were performed in differentiated cells. For 
experiments cells were cultured in serum-free media 24 hours prior to addition of stimuli and throughout 
the experiment. For high glucose experiments, glucose was added in the media to reach a final 
concentration of 700 mg/dl versus control media with 200 mg/dl glucose. The same amount of mannitol 
was added as an osmolarity control. AngII (10-7 mol/L) was added each day (Bachem). Human 
recombinant TGF-β1 (Peprotech, London, UK) was used at a concentration of 10 ng/mL. 
Animal models 
Two groups of ten 10-week-old Wistar Kyoto rats (Criffa, Barcelona, Spain) were studied. 
Diabetes was induced by a single intraperitoneal 50 mg/Kg streptozotocin (STZ) (Sigma, St. Louis, MO) 
injection (5). Control rats received the STZ vehicle (0.01 M citrate buffer pH 4.5). Rats were sacrificed at 
7 months following induction of diabetes (5). Insulin (1-4 IU s.c., Insulatard NPH, Novo Nordisk, 
Denmark) was administered weekly so as to prevent death, but not with the aim of totally correcting 
hyperglycemia. Insulin administration was initiated 7 days after STZ, having checked that glycemia was 
>400 mg/dl (Glucocard, Menarini, Barcelona, Spain). Systolic blood pressure was measured monthly in 
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conscious, restrained rats by the tail-cuff sphygmomanometer (NARCO, Biosystems, CO). Albuminuria 
was measured by ELISA (Celltrend, Luckenwalde, Germany). (Supplemental Table 1). 
In an independent experiment, two groups of 10-week-old Wistar Kyoto rats (Criffa) were 
studied. Diabetes was induced by a single intraperitoneal 50 mg/Kg streptozotocin injection. Rats were 
sacrificed at 6 weeks following induction of diabetes. At that time albuminuria was already increased 
(2310 ± 400  µg/24h vs 440 ± 300 µg/24h in controls, p<0.05). 
AngII 100 ng/kg/min was systemically infused by subcutaneous osmotic minipumps (Alza 
Corp., CA) for 24 hours to 2 weeks to 3-month-old male Wistar rats (n=4-8 animals per group). A control 
group of same age saline-infused rats was also studied (n=8 animals). 
Rats were killed and kidneys perfused in situ with cold saline before removal. One kidney was 
fixed in buffered formalin, embedded in paraffin and used for immunohistochemistry, and the other 
kidney was snap-frozen in liquid nitrogen for RNA and protein studies of renal cortexes. All experimental 
procedures were approved by the Animal Care and Use Committee of our Institution, according to the 
guidelines for ethical care of the European Community. 
Immunohistochemistry and immunofluorescence 
 Immunohistochemistry and immunofluorescence were carried out in paraffin-embedded rat 
kidney sections 5 µm thick (33). The primary antibodies were goat polyclonal anti-HSPB1 (1:60, Santa 
Cruz Biotechnology) and FITC-mouse anti-synaptopodin (1:10, Progen, Heidelberg, Germany). 
Secondary HRP- and phycoerythrin-conjugated antibodies were used for HSPB1. For 
immunohistochemistry sections were counterstained with Carazzi`s hematoxylin. Negative controls 
included incubation with a non-specific immunoglobulin of the same isotype as the primary antibody. 
Western blot 
Western blots were performed as described previously (34). Membranes were incubated 
overnight at 4ºC with rabbit polyclonal anti-HSPB1 antibody (1:500; Santa Cruz Biotechnology), mouse 
monoclonal anti-HSP70 and anti-HSP47 (1:1000, SPA-810, Stressgen), rabbit polyclonal anti–cleaved 
caspase-3 (1:1,000; Cell Signaling, Hertfordshire, U.K.), or mouse anti-tubulin monoclonal antibody 
(1:5000, Sigma, St. Louis, MO) followed by incubation with horseradish peroxidase-conjugated 
secondary antibody (1:2,000, Amersham, Aylesbury, UK). Blots were developed with the enhanced 
chemiluminescence method (ECL) following the manufacturer’s instructions (Amersham). 
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Isolation of glomerular protein 
Kidneys from 7-month diabetic rats and their control were harvested, decapsulated, and 
macerated through three sieves (150, 106, and 63 µm). Tissue trapped by the 63 µm sieve was washed 
with PBS and centrifuged at 4°C for five minutes. The pellet was resuspended in PBS and examined 
under phase contrast microscopy. The preparation contained >95% glomeruli with minimal tubular 
contamination. Then, Western blot was performed as described previously. 
Real time reverse transcription-polymerase chain reaction 
 RNA was isolated by Trizol (Invitrogen, Paisley, UK). One   µg of RNA was reverse transcribed 
with High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). Real-time PCR reactions 
were performed on an ABI Prism 7500 sequence detection PCR system (Applied Biosystems) according 
to manufacturer's protocol using the DeltaDelta Ct method (35). Expression levels are given as ratios to 
GAPDH. Pre-developed primer and probe assays (PDAR) were obtained for human GAPDH and HSPB1 
from Applied Biosystems. 
Confocal microscopy 
Cells plated onto Labtek™ slides were fixed in 4% paraformaldehyde and permeabilized in 0.2% 
Triton X-100 in PBS for 10 min each. After washing in PBS cells were incubated overnight at 4ºC with 
goat polyclonal anti-HSPB1 antibody (1:50, Santa Cruz) followed by incubation with anti-goat Alexa 
Fluor 488 (1:300, Invitrogen). Cell nuclei were counterstained with DAPI (Vector Laboratories, Inc., 
Burlingame, CA) to observe the typical morphological changes. After washing, cells were mounted in 70% 
glycerol in PBS, and analysed with a DM-IRB confocal microscope (Leica DM, Bannockburn, IL) (36).   
Cell death and apoptosis  
Cells were cultured to subconfluence in twelve-well plates. Apoptosis was assessed by functional 
and morphological studies. Flow cytometry of DNA content was used to quantitate apoptosis. Adherent 
cells were pooled with spontaneously detached cells, and stained in 100 µg/mL propidium iodide, 0.05% 
NP-40, 10 µg/mL RNAse A in PBS and incubated at 4°C for >1 hour. This assay permeabilizes the cells. 
Permeabilization allows entry of propidium iodide in all cells, dead and alive. Apoptotic cells are 
characterized by a lower DNA content (hypodiploid cells) because of nuclear fragmentation. Thus, this 
assay is not based on the known ability of propidium iodide to enter dead cells. The percentage of 
apoptotic cells with decreased DNA content (A0) was counted (37;38). Cells were exposed to high (700 
mg/dL) glucose, Ang II (10-7 M) or TGFβ1 (10 ng/mL). 
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To assess the typical apoptotic nuclear changes cells were cultured in chamber slides (Labtek, 
Nunc, Naperville, IL), fixed with methanol:acetone (1:1), and stained with DAPI (Sigma) and anti- 
HSPB1. The typical condensed, shrunk and fragmented nuclei of apoptotic cells were identified by a laser 
scanning confocal microscope (Leika). 
 The ApoScreen Annexin V-FITC kit (Southern Biotechnology Associates, Birmingham, 
Alabama, USA) was used to assess both apoptosis and necrosis by flow cytometry. This method 
discriminates between early apoptotic (propidium iodide negative, annexinV positive), and late apoptotic 
or necrotic cells (propidium iodide positive, annexinV positive) (39). 
Caspase-9 activity was assessed in cells transfected with HSPB1 siRNA and stimulated with Ang 
II or high glucose. Caspase-9 activity (R&D Systems, Minneapolis, MN) was measured following the 
manufacturer’s instructions. In brief, cell extracts (100 µg protein) were incubated in half-area 96-well 
plates at 37°C with 200 µM LEDH-pNA peptide in a total volume of 100 µl. The pNA light emission was 
quantified using a spectrophotometer plate reader at 405 nm. Comparison of the absorbance of pNA from 
an apoptotic sample with an uninduced control allows determination of the fold increase in caspase 
activity. 
Transfection of Small Interfering RNA 
Cells were grown in six-well plates (Costar, Cambridge, MA) and transfected with a mixture of 
25 nmol/mL HSPB1 siRNA (Santa Cruz), Opti-MEM I Reduced Serum Medium and Lipofectamine 2000 
(Invitrogen) (5). Two independent siRNAs were used and similar results were obtained. After 18 hours, 
cells were washed and cultured for 24 hours in complete medium, and serum-depleted for 24 h before 
addition of high glucose or Ang II. This time point was selected from a time-course of decreasing HSPB1 
protein expression in response to siRNA. A negative control scrambled siRNA provided by the 
manufacturer did not reduce HSPB1 protein. 
Human renal biopsies 
Kidney samples were obtained from type 2 diabetes mellitus (n=8) patients biopsied because of 
nephrotic proteinuria. Clinical data at biopsy were: mean age 54 years (range 28 to 78 years); mean serum 
creatinine 2.5 mg/dl (range 1.1 to 3.6 mg/dl); mean proteinuria 6.1 g/d (range 1.0 to 14.5 g/d). Biopsies 
showed a clear picture of diffuse or nodular glomerulosclerosis with a marked tubulointerstitial 
involvement. Normal kidneys were also assessed. Minimal change disease (MCD) was used as a non-
progressive proteinuric control (n=9: mean age 18 years (range 2 to 56 years); mean serum creatinine 
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0.78 mg/dl (range 0.34 to 2.5 mg/dl); mean proteinuria 4.61 g/d (range 0.3 to 14 g/d). Focal segmental 
glomerulosclerosis (FSGS) was studied as a progressive proteinuric disease (n=9: mean age 34 years 
(range 13 to 57 years); mean serum creatinine 1.0 mg/dl (range 0.51 to 1.7 mg/dl), mean proteinuria 5.2 
g/d (range 0.75 to 9.6 g/d). The study protocol was approved by the local Ethics Committee and informed 
consent was obtained. 
Immunohistochemistry was carried out in paraffin-embedded human kidney, fixed in 4% 
buffered formalin, or Bouin. The primary antibody was goat polyclonal anti- HSPB1 (1:5000, Santa Cruz 
biotechnology, CA, USA). Briefly, 5 µm thick renal sections were adhered to polylysine-coated glass 
slides and fixed overnight at 56°C. After deparaffinizing through xylene, alcohol and distilled water, 
endogenous peroxidase was blocked by 3% H2O2 for 10 min. Sections were microwaved in 0.1mM 
citrate buffer pH 6.0 for 20min, and transferred to distilled water. After rinsing in Tris–HCl–phosphate-
buffered saline (TPS), sections were incubated with 1:10 normal rabbit serum in TPS/1% BSA and then 
incubated overnight at 4°C with unlabelled goat anti-human HSPB1. Next, they were incubated with 
biotinylated rabbit anti-goat antibody (1:500) in TPS–1%-BSA for 30 min at 22°C. After three rinses in 
TPS, they were incubated with streptavidin–peroxidase (Dako) 1:500 for 30 min. Color was developed 
with diaminobenzidine and then counterstained with haematoxylin, dehydrated and mounted with 
Canadian balsam (Polysciences, Inc.). Specificity was checked by omission of primary antibodies and use 
of non-immune sera. 
Statistics 
Data are given as mean ± standard deviation. Mann-Whitney, 2-sided t-test or one-way ANOVA 
were applied to indicate significantly different mean values in comparison to the control group. A p value 
< 0.05 was considered statistically significant. 
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RESULTS 
Increased HSPB1 expression in experimental diabetic nephropathy 
Increased podocyte HSPB1 had been observed in rats with nephrotic syndrome induced by PAN 
(25). However, this toxic model has no obvious human counterpart and it was unknown whether similar 
changes occur in subnephrotic proteinuria or podocyte injury induced by endogenous pathophysiological 
stimuli. We studied a chronic rat model of DN induced by a single STZ injection and characterized by the 
development of albuminuria (1071±247 vs 390±70 µg/24h, p<0.02, at 7 months, supplemental table 1). 
At this time point whole kidney HSPB1 mRNA (Figure 1.A) and protein (Figure 1.B) levels were 
increased.  The glomerular HSPB1 mRNA expression was significantly increased in DN compared with 
control rats (Figure 1.C). Immunohistochemistry also localized increased HSPB1 expression to glomeruli 
of DN rats (Figure 1.D), where HSPB1 co-localized with anti-synaptopodin positive podocytes (Figure 
1.E). In an early rat model of DN (6 weeks) in which albuminuria was starting to increase, 
immunohistochemistry showed an increased glomerular HSPB1 expression (Figure 2.A). 
Chronic AngII infusion in rats increased kidney HSPB1 expression 
AngII is a key determinant of DN. AngII infusion in rodents causes renal damage, characterized 
by glomerular and interstitial inflammatory cell infiltration, observed at 3 days, and tubular atrophy and 
interstitial fibrosis found after 2 weeks (40-42). At this time point, Ang II increased total kidney 
HSPB1mRNA and protein levels, as assessed by real time PCR (Figure 2.B) and Western blot (Figure 
2.C), respectively. Immunohistochemistry localized HSPB1 expression to glomeruli, mainly in podocytes 
(Figure 2.D). 
Increased expression of HSPB1 in human diabetic nephropathy 
HSPB1 was studied in normal human kidneys, MCD, DN and FSGS. MCD is a non-progressive 
proteinuric kidney diseases, while both DN and FSGS are characterized by progressive glomerular injury 
and podocyte loss. HSPB1 expression was absent from normal glomeruli or MCD podocytes (Figure 3.A, 
B). Increased glomerular HSPB1 expression was noted by immunohistochemistry in all human DN and 
FSGS biopsies and morphologically localised to podocytes (Figure 3.C,D). HSPB1 tubular staining was 
observed in FSGS and DN and in occasional tubules in MCD. 
Regulation of HSPB1 in cultured human podocytes 
HSPB1 is upregulated in response to stress (43). Since HSPB1 was upregulated in human DN we 
tested the hypothesis that stressed human podocytes could synthesize HSPB1 as a defense mechanism. 
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Based on experimental model results, we tested the regulation of HSPB1 expression by high glucose or 
Ang II, two of the main contributors to the pathogenesis of human DN. Either a high glucose 
concentration or Ang II increased HSPB1 mRNA (Figure 4.A,C) and protein expression in human 
podocytes (Figure 4.B,D). Mannitol, used as an osmolarity control, did not change HSPB1 expression 
(Figure 4.A). 
 
HSPB1 expression is a compensatory mechanism that protects human podocytes from high glucose 
or angiotensin II-induced apoptosis 
Once demonstrated that HSPB1 expression is upregulated by high glucose and Ang II in vivo and in cell 
culture, we approached the function of HSPB1 under these conditions. That is, we assessed the function 
of the increased HSPB1 levels observed in response to an environment found in DN in vivo. High glucose 
induces human podocyte stress and apoptosis (5). To investigate the function of HSPB1 in human 
podocytes exposed to high glucose, HSPB1 was knocked down by using specific siRNAs. Two different 
siRNAs (siRNA1 and siRNA2) were used. Results using siRNA1 are shown in figures 5.B, 5.D, 5.E, 6.B 
and 6.C.  Results using siRNA2 are shown in figures 5.A, 5.C and 6.A. Using siRNA1 we obtained 
similar results to those with siRNA2 shown in figures 5.A, 5.C and 6.A (not shown). Western blot 
confirmed efficient gene silencing of HSPB1 in the absence of changes in the levels of other HSP proteins 
(Figure 5.A). HSPB1 targeting did not modulate cell death in non-stressed cells (Figure 5.B). However, 
HSPB1 knock-down increased the apoptosis rate, assessed as hypodiploid cells, of podocytes stressed by 
a high glucose environment (Figure 5.B). Ang II had a negligible effect on human podocyte apoptosis. 
However, preventing HSPB1 upregulation sensitized to Ang II-induced apoptosis (Figure 5.B). Western 
blot and confocal microscopy confirmed HSPB1 upregulation by high glucose and Ang II at the 
individual cell level, as well as effective HSPB1 downregulation by specific siRNAs (Figure 5.C. D). 
Assessment and quantification of morphological features of apoptosis confirmed the apoptosis sensitizing 
effect of HSPB1 targeting in the presence of high glucose or AngII (Figure 5.E). The results were 
confirmed using a different siRNA and method to assess apoptosis. In this regard, the percentage of 
apoptotic cells assessed as propidium iodide negative, annexin V positive cells was higher after HSPB1 
knock-down with HSPB1 siRNA (Figure 6.A). HSPB1 targeting also increased TGFβ1-induced apoptosis 
(Figure 6.A). These results suggest that HSPB1 upregulation in the presence of DN environmental 
stressors protects human podocytes from stress induced by stimuli present in the DN environment. 
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HSPB1 targeting promotes caspase activation in podocytes 
In the mitochondrial pathway for apoptosis release of cytochrome c from mitochondria promotes 
activation of caspase-9 (44). Caspase-9 promotes activation of downstream caspases, such as caspase-3, 
the central executioner caspase, common to several apoptotic pathways. HSPB1 targeting using specific 
siRNAs promoted caspase-3 activation in podocytes stressed by AngII or by a high glucose environment 
(Figure 6.B). By contrast, caspase-9 activity was increased only in podocytes stressed by AngII (Figure 
6.C) but not in those stressed by a high glucose environment, suggesting that these stressors activate 
different apoptotic pathways that have in common the regulation by HSPB1. 
 
DISCUSSION 
The role of HSPB1 on podocytes exposed to stressors relevant for DN has not been well 
characterized. We now show that in podocytes HSPB1 is upregulated in vivo and in culture by stimuli 
relevant for the pathogenesis of DN, i.e. high glucose and AngII. Indeed, podocyte HSPB1 is increased in 
human DN. HSPB1 upregulation appears to be a compensatory mechanism that prevents or reduces 
podocyte apoptosis induced by high glucose or AngII. In this regard, HSPB1 targeting, effectively 
preventing HSPB1 upregulation by these stimuli, sensitized to apoptosis podocytes stressed by stimuli 
relevant to DN such as high glucose, AngII and TGFβ1. 
HSPB1 is not a classic chaperone as it does not actively refold other proteins. It instead has a 
chaperone-like activity, preventing aggregation of other partially denatured proteins. Thus, HSPB1 
interacts with a large number of different proteins and prevents cell death caused by hyperthermia, 
oxidative stress, staurosporine, Fas ligand and cytotoxic drugs (24;28;45-49). HSPB1 is an antioxidant 
and inhibits multiple steps in the extrinsic and intrinsic mitochondrial apoptotic pathways. However, 
HSPB1 target molecules differ for different lethal stimuli and cell types (50;51). In certain cells HSPB1 
binds to cytochrome c released from mitochondria and HSPB1 overerexpression prevents cytochrome-c-
mediated interaction of Apaf-1 with procaspase-9 and procaspase-9 activation (28;30). In this regard, in 
human podocytes we observed that HSPB1 targeting promoted caspase-9 and caspase-3 activity in the 
presence of Ang II. Caspase-3 may be a downstream target of caspase-9 or other activator caspases (44). 
However, despite no change in caspase-9 activity, HSPB1 targeting increased caspase-3 activation in 
podocytes exposed to high glucose. This suggests caspase-9 independent effects of HSPB1. In this sense, 
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in oocytes HSPB1 targeting promoted caspase-3 activation in the absence of caspase-9 activation, similar 
to the observation in podocytes exposed to high glucose conditions (52). 
 Podocyte injury results in proteinuric renal disease (53). Contrary to MCD, both DN and 
FSGS are progressive glomerular diseases characterized by progressive loss of podocytes in which 
podocyte apoptosis has been observed (13,14). Podocyte HSP27 expression was found in DN or FSGS, 
but not in normal kidney or MCD. This suggests that DN and FSGS may share podocyte stressors that 
result in podocyte loss and that engage podocyte adaptive responses and that these adaptive responses are 
not engaged in MCD. The precise factors contributing to podocyte HSPB1 expression in FSGS may 
include AngII itself, since overexpression of the AT1 receptor in podocytes results in FSGS (54). It is 
interesting to note that in experimental nephrotic syndrome caused by toxin-mediated podocyte injury, 
HSP25 (the mouse homolog of human HSPB1) levels increased (31), and enforced overexpression of 
HSP25 in cultured murine podocytes protected the actin cytoskeleton against toxin-induced disruption 
(55). Previous studies had observed a transient increase in glomerular HSPB1 phosphorylation in short-
term diabetes and p38MAPK-dependent HSPB1 phosphorylation in murine podocytes exposed to high 
glucose, but the role of HSPB1 in glucose-induced apoptosis was not studied (55). HSPB1 may become 
phosphorylated at different serines in response to heat shock and various stimuli (reviewed in 56). The 
p38 MAPK pathway plays a key role in HSPB1 phosphorylation, also in podocytes (57). Indeed high 
glucose promotes HSPB1 phosphorylation in renal cells in an MK(MAPKAP)-2-dependent manner (58).  
The phosphorylation state of HSPB1 can influence its function. Thus, it modulates the size of HSPB1 
oligomers and facilitates the nuclear migration of the protein (59). HSPB1 phosphorylation may influence 
the fate of the cell in response to an apoptotic stimulus, although the requirement for phosphorylation may 
vary in different systems (60). A phosphorylation-defective mutant HSPB1 accelerated toxin-induced 
apoptosis in renal epithelial cells (61). Overexpression of the wild-type HSPB1, but not a non-
phosphorylatable mutant, markedly reduced complement-mediated glomerular epithelial cell injury (62). 
Indeed increased glomerular HSPB1 phosphorylation was noted in experimental toxin-induced nephrotic 
syndrome and diabetes, but decreased in ischemia (58;63;64). However, prevention of renal HSPB1 
phosphorylation did not interfere with the development of early diabetic nephropathy in diabetic mice 
(58). 
In renal tubular cells, HSPB1 overexpression inhibited apoptosis and HSPB1 knockdown 
promoted apoptosis in response to culture in glucose-free medium containing sodium cyanide and 2-
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deoxy-d-glucose (51). However, this kind of metabolic stress is of dubious clinical significance in the 
particular setting of DN. We now show that glomerular HSPB1 is upregulated in humans and in rats with 
short- (6 weeks) and long-standing (7 months) DN and that podocytes are key sources of glomerular 
HSPB1 in both clinical and experimental DN. This appears to be the consequence, at least in part, of high 
glucose levels, since high glucose upregulated HSPB1 in cultured human podocytes. High glucose is 
known to promote renal cell apoptosis, including podocyte apoptosis (3;5). We have observed that 
impairing the HSPB1 upregulation adaptive response by siRNA targeting sensitizes to high glucose-
induced apoptosis, while having a negligible effect on spontaneous apoptosis. Thus, these studies expand 
previous data by showing that stimuli pathophysiologically relevant to DN, such as high glucose, increase 
podocyte HSPB1 and also by showing that prevention of this upregulation promotes apoptosis. Thus, 
even when not reaching very high HSPB1 levels as a consequence of enforced expression in transiently 
transfected cells, HSPB1 is also protective. 
In DN high levels of glucose recruit secondary mediators of injury that aggravate and perpetuate 
renal injury. Ang II is the secondary mediator of DN with most clinical relevance. Ang II has hormonal as 
well as paracrine/autocrine functions that modulate renal injury. Overexpression of podocyte Ang II type 
1 receptor in rats results in proteinuria, nephron loss, and glomerulosclerosis (54). Inhibition of RAS 
activity lowers proteinuria and slows progression to end-stage renal disease, and is the keystone of human 
DN therapy (65;66). HSPB1 had previously been shown to be upregulated in the kidney by short-term 
(<1 week) Ang II infusion (67). However, the glomerular location of HSPB1 upregulation was not 
described and the function of HSPB1 was not addressed (67). We now show glomerular HSPB1 
upregulation in a model of chronic infusion of Ang II, in vivo localization of HSPB1 expression to 
podocytes, and a direct effect of Ang II on cultured podocytes promoting HSPB1 upregulation. As in the 
case of high glucose exposure, inhibition of HSPB1 expression promotes Ang II-induced apoptosis. Thus, 
upregulation of HSPB1 in response to Ang II is a podocyte adaptive response to prevent Ang II- and also 
TGFβ1-induced cell death. Further studies should explore whether HSPB1 might also regulate additional 
proinflammatory actions of AngII (68). 
In conclusion, HSPB1 is upregulated in vivo and in cultured podocytes by high glucose and Ang 
II. This appears to be an adaptive response that allows podocytes to cope with these stressors and prevents 
apoptosis since depletion of this upregulated HSPB1 sensitized to these same stimuli. Increased amounts 
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of endogenous HSPB1 are required to prevent podocyte apoptosis in a diabetic milieu rich in glucose and 
Ang II. This may lead to the development of new therapeutic approaches. 
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TITLES AND LEGENDS TO FIGURES 
Figure 1. Expression of HSPB1 in experimental diabetic nephropathy. A) Whole kidney HSPB1 
mRNA was increased in diabetic rats when compared to controls. Mean ±SD of 10 rats per group. 
*p<0.04 vs control rats. B) Quantification and representative image of Western blot of whole kidney 
protein. Western blot quantification expressed as percentage increase over control. Mean±SD of 10 rats 
per group. *p<0.006 vs control rats. C) Western blot analysis of glomerular HSPB1. Mean±SD of 10 rats 
per group. *p<0.03 vs control rats.  D) Immunohistochemistry, representative images of control and DN 
kidney in which podocyte staining for HSPB1 is observed (arrows). Original magnification x200 and 
x400. D) Double anti-synaptopodin (green) and anti- HSPB1 (red) staining of glomeruli in rat DN. Anti-
synaptopodin stains mainly the foot processes and less intensely the podocyte body and the area near the 
cell membrane, while anti-HSPB1 stains mainly the podocyte body. Several clearly identifiable podocytes 
are indicated by arrows. Original magnification x400. 
Figure 2. Renal HSPB1 expression is upregulated in early diabetic nephropathy and chronic AngII 
infusion. A) HSPB1 immunohistochemistry, representative images of control and DN rat kidney at week 
6 following injection of streptozotocin or vehicle. Podocyte staining for HSPB1 is observed in DN. 
Original magnification x200 and x400. B) Whole kidney HSPB1 mRNA was increased in Ang II-infused 
rats when compared to controls. Mean±SD of 6-8 animals per group. *p<0.008 vs control. C) 
Quantification and representative image of Western blot of whole kidney protein. Mean±SD of 6-8 animals 
per group. *p<0.01 vs control. D) Representative immunohistochemistry where HSPB1 is increased in the 
glomeruli in a distribution suggestive of podocyte expression. Original magnification x200 and x400. 
Figure 3. Increased HSPB1 expression in human diabetic nephropathy biopsies. A) Representative 
images of normal kidneys. B) Minimal change disease (MCD). C) Diabetic nephropathy (DN). D) Focal 
segmental glomerulosclerosis (FSGS). HSPB1 immunohistochemistry. Note a marked increase in HSPB1 
staining in glomerular cells with a podocyte localization (arrow) in DN and FSGS. Original magnification 
x200 and x400. 
Figure 4. High glucose and Ang II increase  HSPB1 expression in cultured human podocytes. Cells 
were exposed to A,B) high glucose or C,D) Ang II. High glucose (A) or Ang II (C) increases HSPB1 
mRNA in a time-dependent manner. Real time RT-PCR. Mean±SD of 3 independent experiments. 
*p<0.03 vs control 24 hours. B and D) Quantification and representative Western blot of HSPB1. Cells 
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were cultured in the presence of B) high glucose and D) Ang II for 24 h. Mean±SD of 3 independent 
experiments. *p<0.04 vs control. 
Figure 5. Inhibition of HSPB1 expression by siRNA sensitizes to apoptosis in human podocytes. A) 
HSPB1 siRNA downregulation of HSPB1. Representative Western blot of the specific siRNA.  B) 
HSPB1 knock-down with HSPB1 siRNA increases high glucose-induced apoptosis and promotes Ang II-
induced apoptosis. Cell death was assessed by flow cytometry of DNA content (hypodiploid cells) after 
culture in the presence of high glucose or Ang II (10-7 M) for 24h. Mean±SD of 3 independent 
experiments. *p<0.05 versus control; ** p<0.001 vs high glucose; #p<0.03 vs Ang II alone. C) 
Representative Western blot corresponding to the conditions of the experiment shown in B. D) HSPB1 
silencing increased apoptosis in human podocytes as assessed by morphology. Representative image of 
apoptotic cells with typical nuclei (shrunk, bright) (DAPI staining) among cells transfected with HSPB1 
siRNA (arrows). Anti-HSPB1 staining in green confirmed upregulation of HSPB1 expression by high 
glucose or Ang II and effective downregulation by siRNA. E) Quantification of apoptotic cells expressed 
as percentage of cells with apoptotic nuclei as assessed by DAPI staining. Mean ±SD for 3 independent 
experiments. *p<0.009 vs high glucose and Ang-II alone; **p<0.0001 vs control; #p<0.04 vs control. 
 
Figure 6. Inhibition of HSPB1 expression by siRNA sensitizes to apoptosis promoting caspase 
activation in human podocytes. A) HSPB1 knock-down with HSPB1 siRNA increases high glucose- 
and TGFβ1-induced apoptosis and promotes Ang II-induced apoptosis. Cell death was assessed by flow 
cytometry following staining with propidium iodide and annexinV after culture in the presence of high 
glucose, Ang II (10-7 M) or TGFβ1 (10 ng/mL) for 24h. Representative experiment. B) Podocyte 
apoptosis induced by HSPB1 knocked down with HSPB1 siRNA is associated with caspase activation. 
Caspase-3 is processed in the course of Ang II- and high glucose-induced apoptosis when HSPB1 is 
knocked down. Quantification of active caspase 3 Western blot. Mean ±SD for 3 independent 
experiments * p<0.001 vs Angiotensin, **p<0.004 vs high glucose. C) HSPB1 knock-down promotes 
caspase-9 activity in human podocytes exposed to AngII. Mean ±SD for 3 independent experiments * 
p<0.02 vs control, **p<0.05 vs Angiotensin alone. 
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